To conclude, this pilot study demonstrated that combined genotype analysis of GSTP1, TS-5′ 28bp and TS-5′ G → C polymorphisms may contribute to the selection of gastric cancer patients who would benefit most from 5-FU/cisplatin combination chemotherapy. The gene discussed is TYMS; the disease is gastric cancer.